| URL | https://www.wraltechwire.com/2021/12/15/durham-gen |
| Source | WRAL |
| Date Published | 12/15/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Pfizer |
| Parent company | Pfizer |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 50 |
| Year reshoring announced: | 2021 |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | gene therapy |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training |